BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 31546305)

  • 1. Trehalose Protects the Probiotic Yeast
    Moon JE; Heo W; Lee SH; Lee SH; Lee HG; Lee JH; Kim YJ
    J Microbiol Biotechnol; 2020 Jan; 30(1):54-61. PubMed ID: 31546305
    [No Abstract]   [Full Text] [Related]  

  • 2. S-Adenosyl-L-methionine protects the probiotic yeast, Saccharomyces boulardii, from acid-induced cell death.
    Cascio V; Gittings D; Merloni K; Hurton M; Laprade D; Austriaco N
    BMC Microbiol; 2013 Feb; 13():35. PubMed ID: 23402325
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preparation of
    Shu G; Li B; Dai C; Chen L; Yang X; Lei Z; Zhang M; Guo Y
    Prep Biochem Biotechnol; 2022; 52(9):1078-1086. PubMed ID: 35108154
    [No Abstract]   [Full Text] [Related]  

  • 4. Epidemiology of Saccharomyces fungemia: A systematic review.
    Vinayagamoorthy K; Pentapati KC; Prakash H
    Med Mycol; 2023 Feb; 61(2):. PubMed ID: 36806741
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Growth, survival, and metabolic activities of probiotics Lactobacillus rhamnosus GG and Saccharomyces cerevisiae var. boulardii CNCM-I745 in fermented coffee brews.
    Chan MZA; Toh M; Liu SQ
    Int J Food Microbiol; 2021 Jul; 350():109229. PubMed ID: 34023682
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Unique Properties of Yeast Probiotic Saccharomyces boulardii CNCM I-745: A Narrative Review.
    Gopalan S; Ganapathy S; Mitra M; Neha ; Kumar Joshi D; Veligandla KC; Rathod R; Kotak BP
    Cureus; 2023 Oct; 15(10):e46314. PubMed ID: 37927652
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Saccharomyces boulardii CNCM I-745: A Non-bacterial Microorganism Used as Probiotic Agent in Supporting Treatment of Selected Diseases.
    Kaźmierczak-Siedlecka K; Ruszkowski J; Fic M; Folwarski M; Makarewicz W
    Curr Microbiol; 2020 Sep; 77(9):1987-1996. PubMed ID: 32472262
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fungemia following Saccharomyces cerevisiae var. boulardii probiotic treatment in an elderly patient.
    Landaburu MF; López Daneri GA; Relloso S; Zarlenga LJ; Vinante MA; Mujica MT
    Rev Argent Microbiol; 2020; 52(1):27-30. PubMed ID: 31262611
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Review article: yeast as probiotics -- Saccharomyces boulardii.
    Czerucka D; Piche T; Rampal P
    Aliment Pharmacol Ther; 2007 Sep; 26(6):767-78. PubMed ID: 17767461
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhancing probiotic impact: engineering
    de Carvalho BT; Subotić A; Vandecruys P; Deleu S; Vermeire S; Thevelein JM
    Appl Environ Microbiol; 2024 Jun; 90(6):e0032524. PubMed ID: 38752748
    [No Abstract]   [Full Text] [Related]  

  • 11. Prospective randomized controlled study on the effects of Saccharomyces boulardii CNCM I-745 and amoxicillin-clavulanate or the combination on the gut microbiota of healthy volunteers.
    Kabbani TA; Pallav K; Dowd SE; Villafuerte-Galvez J; Vanga RR; Castillo NE; Hansen J; Dennis M; Leffler DA; Kelly CP
    Gut Microbes; 2017 Jan; 8(1):17-32. PubMed ID: 27973989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comprehensive optimization of composite cryoprotectant for
    Guowei S; Yang X; Li C; Huang D; Lei Z; He C
    Prep Biochem Biotechnol; 2019; 49(9):846-857. PubMed ID: 31244369
    [No Abstract]   [Full Text] [Related]  

  • 13. Incidence of Saccharomyces cerevisiae fungemia in hospitalised patients administered Saccharomyces boulardii probiotic.
    Wombwell E; Bransteitter B; Gillen LR
    Mycoses; 2021 Dec; 64(12):1521-1526. PubMed ID: 34585799
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unique genetic basis of the distinct antibiotic potency of high acetic acid production in the probiotic yeast
    Offei B; Vandecruys P; De Graeve S; Foulquié-Moreno MR; Thevelein JM
    Genome Res; 2019 Sep; 29(9):1478-1494. PubMed ID: 31467028
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Production of neoagarooligosaccharides by probiotic yeast Saccharomyces cerevisiae var. boulardii engineered as a microbial cell factory.
    Jin Y; Yu S; Liu JJ; Yun EJ; Lee JW; Jin YS; Kim KH
    Microb Cell Fact; 2021 Aug; 20(1):160. PubMed ID: 34407819
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Saccharomyces boulardii ameliorates gut dysbiosis associated cognitive decline.
    Roy Sarkar S; Mitra Mazumder P; Chatterjee K; Sarkar A; Adhikary M; Mukhopadhyay K; Banerjee S
    Physiol Behav; 2021 Jul; 236():113411. PubMed ID: 33811908
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Effect of a Yeast Probiotic on Acute Diarrhea in Children.
    Sharif MR; Kashani HH; Ardakani AT; Kheirkhah D; Tabatabaei F; Sharif A
    Probiotics Antimicrob Proteins; 2016 Dec; 8(4):211-214. PubMed ID: 27530282
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Yeasts as probiotics: Mechanisms, outcomes, and future potential.
    Sen S; Mansell TJ
    Fungal Genet Biol; 2020 Apr; 137():103333. PubMed ID: 31923554
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Saccharomyces boulardii CNCM I-745 probiotic does not alter the pharmacokinetics of amoxicillin.
    Selig DJ; DeLuca JP; Li Q; Lin H; Nguyen K; Scott SM; Sousa JC; Vuong CT; Xie LH; Livezey JR
    Drug Metab Pers Ther; 2020 Mar; 35(1):. PubMed ID: 32134728
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Saccharomyces boulardii as therapeutic alternative in experimental giardiasis.
    Ribeiro MRS; Oliveira DR; Caliari MV; Cara Machado DC; Andrade MER; Cardoso VN; Dos Santos Martins F; Nicoli JR; Gomes MA
    J Appl Microbiol; 2021 Jul; 131(1):460-469. PubMed ID: 33289232
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.